Allelic variation at the interleukin 1 β gene is associated with decreased bone mass in patients with inflammatory bowel diseases

A. Nemetz, M. Tóth, M. A. García-González, T. Zágoni, J. Fehér, A. S. Peña, Z. Tulassay

Research output: Contribution to journalArticle

57 Citations (Scopus)

Abstract

Background - Interleukin 1β (IL-1β) and its natural antagonist have been implicated in the pathogenesis of inflammatory bowel disease (IBD). Both cytokines influence bone formation. IL-1β stimulates osteoclast activity while interleukin 1 receptor antagonist (IL-1ra) enhances bone formation. Aims - To determine whether the decreased bone mass in IBD is related to gene polymorphisms coding for IL-1β and IL-Ira, and thus identify patients with an increased risk. Methods - Bone mineral densitometry was performed at the femoral neck, lumbar spine, and the distal third of the radius in 75 IBD patients (34 men/41 women; 40.3 (1.6) years) and in 58 healthy controls (HC; 28 men/30 women; 32.4 (1.2) years). Values were correlated with the TaqI and AvaI gene polymorphisms in the IL1B and the variable number of tandem repeats gene polymorphism in the IL1RN gene. Results - In IBD patients, but not in HC, carriers of allele 2 at the AvaI gene polymorphism (IL1B-511*2) had significantly lower Z scores at the lumbar spine (-0.82 (0.13) v-0.29 (0.21) p=0.03) and the femoral neck (-0.59 (0.14) v 0.15 (0.19); p=0.003) than non-carriers. These patients also had a higher risk for osteopenia or osteoporosis at the femoral neck (odds ratio 3.63 (95% confidence interval 0.95-13.93)). No association was found between bone mass and the other gene polymorphisms analysed in IBD patients or in HC. Conclusions - Our results suggest that genetic variability may be a major determinant of bone loss in IBD. Carriers of IL1B-511*2, who are hypersecretors of IL-1β, have a higher risk of presenting with low bone mass in IBD. Screening for this allele may contribute to determination of the risk of bone loss at the time of disease onset.

Original languageEnglish
Pages (from-to)644-649
Number of pages6
JournalGut
Volume49
Issue number5
DOIs
Publication statusPublished - 2001

Fingerprint

Interleukin-1
Inflammatory Bowel Diseases
Bone and Bones
Femur Neck
Genes
Osteogenesis
Spine
Alleles
Minisatellite Repeats
Interleukin-1 Receptors
Densitometry
Metabolic Bone Diseases
Osteoclasts
Osteoporosis
Minerals
Odds Ratio
Confidence Intervals
Cytokines

Keywords

  • Bone density
  • Crohn's disease
  • Genetic polymorphisms
  • Inflammatory bowel diseases
  • Interleukin 1
  • Osteoporosis
  • Ulcerative colitis

ASJC Scopus subject areas

  • Gastroenterology

Cite this

Allelic variation at the interleukin 1 β gene is associated with decreased bone mass in patients with inflammatory bowel diseases. / Nemetz, A.; Tóth, M.; García-González, M. A.; Zágoni, T.; Fehér, J.; Peña, A. S.; Tulassay, Z.

In: Gut, Vol. 49, No. 5, 2001, p. 644-649.

Research output: Contribution to journalArticle

@article{bbbe77d13b8548a99917d5a1c4c4ea56,
title = "Allelic variation at the interleukin 1 β gene is associated with decreased bone mass in patients with inflammatory bowel diseases",
abstract = "Background - Interleukin 1β (IL-1β) and its natural antagonist have been implicated in the pathogenesis of inflammatory bowel disease (IBD). Both cytokines influence bone formation. IL-1β stimulates osteoclast activity while interleukin 1 receptor antagonist (IL-1ra) enhances bone formation. Aims - To determine whether the decreased bone mass in IBD is related to gene polymorphisms coding for IL-1β and IL-Ira, and thus identify patients with an increased risk. Methods - Bone mineral densitometry was performed at the femoral neck, lumbar spine, and the distal third of the radius in 75 IBD patients (34 men/41 women; 40.3 (1.6) years) and in 58 healthy controls (HC; 28 men/30 women; 32.4 (1.2) years). Values were correlated with the TaqI and AvaI gene polymorphisms in the IL1B and the variable number of tandem repeats gene polymorphism in the IL1RN gene. Results - In IBD patients, but not in HC, carriers of allele 2 at the AvaI gene polymorphism (IL1B-511*2) had significantly lower Z scores at the lumbar spine (-0.82 (0.13) v-0.29 (0.21) p=0.03) and the femoral neck (-0.59 (0.14) v 0.15 (0.19); p=0.003) than non-carriers. These patients also had a higher risk for osteopenia or osteoporosis at the femoral neck (odds ratio 3.63 (95{\%} confidence interval 0.95-13.93)). No association was found between bone mass and the other gene polymorphisms analysed in IBD patients or in HC. Conclusions - Our results suggest that genetic variability may be a major determinant of bone loss in IBD. Carriers of IL1B-511*2, who are hypersecretors of IL-1β, have a higher risk of presenting with low bone mass in IBD. Screening for this allele may contribute to determination of the risk of bone loss at the time of disease onset.",
keywords = "Bone density, Crohn's disease, Genetic polymorphisms, Inflammatory bowel diseases, Interleukin 1, Osteoporosis, Ulcerative colitis",
author = "A. Nemetz and M. T{\'o}th and Garc{\'i}a-Gonz{\'a}lez, {M. A.} and T. Z{\'a}goni and J. Feh{\'e}r and Pe{\~n}a, {A. S.} and Z. Tulassay",
year = "2001",
doi = "10.1136/gut.49.5.644",
language = "English",
volume = "49",
pages = "644--649",
journal = "Gut",
issn = "0017-5749",
publisher = "BMJ Publishing Group",
number = "5",

}

TY - JOUR

T1 - Allelic variation at the interleukin 1 β gene is associated with decreased bone mass in patients with inflammatory bowel diseases

AU - Nemetz, A.

AU - Tóth, M.

AU - García-González, M. A.

AU - Zágoni, T.

AU - Fehér, J.

AU - Peña, A. S.

AU - Tulassay, Z.

PY - 2001

Y1 - 2001

N2 - Background - Interleukin 1β (IL-1β) and its natural antagonist have been implicated in the pathogenesis of inflammatory bowel disease (IBD). Both cytokines influence bone formation. IL-1β stimulates osteoclast activity while interleukin 1 receptor antagonist (IL-1ra) enhances bone formation. Aims - To determine whether the decreased bone mass in IBD is related to gene polymorphisms coding for IL-1β and IL-Ira, and thus identify patients with an increased risk. Methods - Bone mineral densitometry was performed at the femoral neck, lumbar spine, and the distal third of the radius in 75 IBD patients (34 men/41 women; 40.3 (1.6) years) and in 58 healthy controls (HC; 28 men/30 women; 32.4 (1.2) years). Values were correlated with the TaqI and AvaI gene polymorphisms in the IL1B and the variable number of tandem repeats gene polymorphism in the IL1RN gene. Results - In IBD patients, but not in HC, carriers of allele 2 at the AvaI gene polymorphism (IL1B-511*2) had significantly lower Z scores at the lumbar spine (-0.82 (0.13) v-0.29 (0.21) p=0.03) and the femoral neck (-0.59 (0.14) v 0.15 (0.19); p=0.003) than non-carriers. These patients also had a higher risk for osteopenia or osteoporosis at the femoral neck (odds ratio 3.63 (95% confidence interval 0.95-13.93)). No association was found between bone mass and the other gene polymorphisms analysed in IBD patients or in HC. Conclusions - Our results suggest that genetic variability may be a major determinant of bone loss in IBD. Carriers of IL1B-511*2, who are hypersecretors of IL-1β, have a higher risk of presenting with low bone mass in IBD. Screening for this allele may contribute to determination of the risk of bone loss at the time of disease onset.

AB - Background - Interleukin 1β (IL-1β) and its natural antagonist have been implicated in the pathogenesis of inflammatory bowel disease (IBD). Both cytokines influence bone formation. IL-1β stimulates osteoclast activity while interleukin 1 receptor antagonist (IL-1ra) enhances bone formation. Aims - To determine whether the decreased bone mass in IBD is related to gene polymorphisms coding for IL-1β and IL-Ira, and thus identify patients with an increased risk. Methods - Bone mineral densitometry was performed at the femoral neck, lumbar spine, and the distal third of the radius in 75 IBD patients (34 men/41 women; 40.3 (1.6) years) and in 58 healthy controls (HC; 28 men/30 women; 32.4 (1.2) years). Values were correlated with the TaqI and AvaI gene polymorphisms in the IL1B and the variable number of tandem repeats gene polymorphism in the IL1RN gene. Results - In IBD patients, but not in HC, carriers of allele 2 at the AvaI gene polymorphism (IL1B-511*2) had significantly lower Z scores at the lumbar spine (-0.82 (0.13) v-0.29 (0.21) p=0.03) and the femoral neck (-0.59 (0.14) v 0.15 (0.19); p=0.003) than non-carriers. These patients also had a higher risk for osteopenia or osteoporosis at the femoral neck (odds ratio 3.63 (95% confidence interval 0.95-13.93)). No association was found between bone mass and the other gene polymorphisms analysed in IBD patients or in HC. Conclusions - Our results suggest that genetic variability may be a major determinant of bone loss in IBD. Carriers of IL1B-511*2, who are hypersecretors of IL-1β, have a higher risk of presenting with low bone mass in IBD. Screening for this allele may contribute to determination of the risk of bone loss at the time of disease onset.

KW - Bone density

KW - Crohn's disease

KW - Genetic polymorphisms

KW - Inflammatory bowel diseases

KW - Interleukin 1

KW - Osteoporosis

KW - Ulcerative colitis

UR - http://www.scopus.com/inward/record.url?scp=0034776454&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0034776454&partnerID=8YFLogxK

U2 - 10.1136/gut.49.5.644

DO - 10.1136/gut.49.5.644

M3 - Article

C2 - 11600466

AN - SCOPUS:0034776454

VL - 49

SP - 644

EP - 649

JO - Gut

JF - Gut

SN - 0017-5749

IS - 5

ER -